The World Health Organization has given its nod to the first malaria vaccine RTS,S (trade name Mosquirix), which has been developed by GlaxoSmithKline. Dr Satyajit Rath, an immunologist and adjunct faculty at IISER, Pune, talks to Newsclick’s editor-in-chief Prabir Purkayastha on the implications of Mosquirix and its role in the fight against malaria in the Global South. He further explains how private companies aim to profit from the vaccine with malaria being a “disease of the poor”.
Why did it take over 50 years to develop Mosquirix, the first anti-malaria vaccine?
Dr Satyajit Rath talks about why it took so long to develop a malaria vaccine and the chances that pharma companies might seek to make big profits out of it
